New nanoparticles to fight antibiotic-resistant infections
Dual-Stimuli Responsive Antibiotic-Loaded Nanoparticles: A New Strategy to Overcome Antimicrobial Resistance
This study is exploring new tiny particles that can help deliver antibiotics more effectively to people dealing with tough bacterial infections that don't respond to regular treatments, making it easier for the medicine to reach the right spot in the body and work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11110295 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticles that can deliver antibiotics more effectively to combat multidrug-resistant bacterial infections. The nanoparticles are designed to respond to specific triggers in the body, such as high levels of reactive oxygen species and low pH, which are common in infected tissues. By encapsulating FDA-approved antibiotics, these nanoparticles aim to enhance the stability and delivery of the drugs directly to the site of infection, improving treatment outcomes for patients with resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug-resistant bacteria, particularly those who have not responded to standard antibiotic treatments.
Not a fit: Patients with infections caused by bacteria that are not multidrug-resistant may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in using nanoparticles for drug delivery, indicating that this approach may lead to significant advancements in treating resistant infections.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Gong, Shaoqin - — University of Wisconsin-Madison
- Study coordinator: Gong, Shaoqin -
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.